Underlying modal data issues for detecting damage in truss structures

Independent of the modal identification techniques employed for damage detection, use of measured modal data limits the expectations for damage location. These limitations are examined using the distribution of modal strain energy and the sensitivity of the frequency and mode shapes to structural stiffness changes. For given measured modal information of specific accuracy, this examination reveals the following: (1) damage detection is feasible for members that contribute significantly to the strain energy of the measured modes, (2) the modes which are most effective in detecting damage to certain critical members can be identified, and (3) a relationship can be drawn between the accuracy of the measured modes and frequencies and damage detection feasibility

Understanding and Evaluating Assurance Cases

Assurance cases are a method for providing assurance for a system by giving an argument to justify a claim about the system, based on evidence about its design, development, and tested behavior. In comparison with assurance based on guidelines or standards (which essentially specify only the evidence to be produced), the chief novelty in assurance cases is provision of an explicit argument. In principle, this can allow assurance cases to be more finely tuned to the specific circumstances of the system, and more agile than guidelines in adapting to new techniques and applications. The first part of this report (Sections 1-4) provides an introduction to assurance cases. Although this material should be accessible to all those with an interest in these topics, the examples focus on software for airborne systems, traditionally assured using the DO-178C guidelines and its predecessors. A brief survey of some existing assurance cases is provided in Section 5. The second part (Section 6) considers the criteria, methods, and tools that may be used to evaluate whether an assurance case provides sufficient confidence that a particular system or service is fit for its intended use. An assurance case cannot provide unequivocal "proof" for its claim, so much of the discussion focuses on the interpretation of such less-than-definitive arguments, and on methods to counteract confirmation bias and other fallibilities in human reasoning

Fiber Optic Control System integration for advanced aircraft. Electro-optic and sensor fabrication, integration, and environmental testing for flight control systems

This report describes the design, development, and testing of passive fiber optic sensors and a multiplexing electro-optic architecture (EOA) for installation and flight test on a NASA-owned F-18 aircraft. This hardware was developed under the Fiber Optic Control Systems for Advanced Aircraft program, part of a multiyear NASA initiative to design, develop, and demonstrate through flight test 'fly-by-light' systems for application to advanced aircraft flight and propulsion control. This development included the design and production of 10 passive optical sensors and associated multiplexed EOA hardware based on wavelength division multiplexed (WDM) technology. A variety of sensor types (rotary position, linear position, temperature, and pressure) incorporating a broad range of sensor technologies (WDM analog, WDM digital, analog microbend, and fluorescent time rate of decay) were obtained from different manufacturers and functionally integrated with an independently designed EOA. The sensors were built for installation in a variety of aircraft locations, placing the sensors in a variety of harsh environments. The sensors and EOA were designed and built to have the resulting devices be as close as practical to a production system. The integrated system was delivered to NASA for flight testing on a NASA-owned F-18 aircraft. Development and integration testing of the system provided valuable information as to which sensor types were simplest to design and build for a military aircraft environment and which types were simplest to operate with a multiplexed EOA. Not all sensor types met the full range of performance and environmental requirements. EOA development problems provided information on directions to pursue in future fly-by-light flight control development programs. Lessons learned in the development of the EOA and sensor hardware are summarized

The Earliest Stage of Galactic Star Formation

Using a recently-developed technique to estimate gas temperatures ($T_\textrm{SF}$) in star-forming regions from large photometric surveys, we propose a diagram, analogous to the Hertzsprung-Russell diagram for individual stars, to probe the evolution of individual galaxies. On this $T_\textrm{SF}$-sSFR (specific star formation rate) diagram, a small fraction of star-forming galaxies appear to be dominated by different feedback mechanisms than typical star-forming galaxies. These galaxies generically have younger stellar populations, lower stellar masses and increase in relative abundance towards higher redshifts, so we argue that these objects are in an earlier stage of galactic star formation. Further, Hubble observations find that these "core-forming" galaxies also exhibit distinct morphology, and that tracks on the $T_\textrm{SF}$-sSFR diagram are also a morphological sequence. Thus, unlike starburst phases which can be triggered environmentally, these earliest, core-forming galaxies, appear to be a stage that typical galaxies go through early in their star formation history. We therefore argue that most galaxies first go through a core formation stage, then subsequently disk formation, and finally become quiescent.Comment: ApJL 949, L3

Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay

BACKGROUND: This study assessed the Granzyme B (GrB) ELISPOT as a viable alternative to the (51)Cr-release assay for measuring cytotoxic activity of innate immune effector cells. We strategically selected the GrB ELISPOT assay because GrB is a hallmark effector molecule of cell-mediated destruction of target cells. METHODS: We optimized the GrB ELISPOT assay using the human-derived TALL-104 cytotoxic cell line as effectors against K562 target cells. Titration studies were performed to assess whether the ELISPOT assay could accurately enumerate the number of GrB-secreting effector cells. TALL-104 were treated with various secretion inhibitors and utilized in the GrB ELISPOT to determine if GrB measured in the ELISPOT was due to degranulation of effector cells. Additionally, CD107a expression on effector cells after effector-target interaction was utilized to further confirm the mechanism of GrB release by TALL-104 and lymphokine-activated killer (LAK) cells. Direct comparisons between the GrB ELISPOT, the IFN-γ ELISPOT and the standard (51)Cr-release assays were made using human LAK cells. RESULTS: Titration studies demonstrated a strong correlation between the number of TALL-104 and LAK effector cells and the number of GrB spots per well. GrB secretion was detectable within 10 min of effector-target contact with optimal secretion observed at 3–4 h; in contrast, optimal IFN-γ secretion was not observed until 24 h. The protein secretion inhibitor, brefeldin A, did not inhibit the release of GrB but did abrogate IFN-γ production by TALL-104 cells. GrB secretion was abrogated by BAPTA-AM (1,2-bis-(2-aminophenoxy)ethane-N,N,N', N'-tetraacetic acid tetra(acetoxymethyl) ester), which sequesters intracellular Ca(2+), thereby preventing degranulation. The number of effector cells expressing the degranulation associated glycoprotein CD107a increased after interaction with target cells and correlated with the stimulated release of GrB measured in the ELISPOT assay. CONCLUSIONS: Because of its high sensitivity and ability to estimate cytotoxic effector cell frequency, the GrB ELISPOT assay is a viable alternative to the (51)Cr-release assay to measure MHC non-restricted cytotoxic activity of innate immune cells. Compared to the IFN-γ ELISPOT assay, the GrB ELISPOT may be a more direct measure of cytotoxic cell activity. Because GrB is one of the primary effector molecules in natural killer (NK) cell-mediated killing, detection and enumeration of GrB secreting effector cells can provide valuable insight with regards to innate immunological responses

Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens.

OBJECTIVES: Flat epithelial atypia (FEA) is a relatively new diagnostic term with uncertain clinical significance for surgical management. Any implied risk of invasive breast cancer associated with FEA is contingent upon diagnostic reproducibility, yet little is known regarding its use. MATERIALS AND METHODS: Pathologists in the Breast Pathology Study interpreted one of four 60-case test sets, one slide per case, constructed from 240 breast biopsy specimens. An electronic data form with standardized diagnostic categories was used; participants were instructed to indicate all diagnoses present. We assessed participants\u27 use of FEA as a diagnostic term within: 1) each test set; 2) 72 cases classified by reference as benign without FEA; and 3) six cases classified by reference as FEA. 115 pathologists participated, providing 6900 total independent assessments. RESULTS: Notation of FEA ranged from 0% to 35% of the cases interpreted, with most pathologists noting FEA on 4 or more test cases. At least one participant noted FEA in 34 of the 72 benign non-FEA cases. For the 6 reference FEA cases, participant agreement with the case reference FEA diagnosis ranged from 17% to 52%; diagnoses noted by participating pathologists for these FEA cases included columnar cell hyperplasia, usual ductal hyperplasia, atypical lobular hyperplasia, and atypical ductal hyperplasia. CONCLUSIONS: We observed wide variation in the diagnosis of FEA among U.S. pathologists. This suggests that perceptions of diagnostic criteria and any implied risk associated with FEA may also vary. Surgical excision following a core biopsy diagnosis of FEA should be reconsidered and studied further